Skip to main content
SpringerLink
Log in

Authors' Reply to Courtney Suggs and Colleagues’ Comment on: “Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs”

  • Letter to the Editor
  • Published:
Drug Safety Aims and scope Submit manuscript

The Original Article was published on 19 September 2018

The Original Article was published on 19 September 2018

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cheng N, Rahman MM, Alatawi Y, Qian J, Peissig PL, Berg RL, et al. Mixed approach retrospective analyses of suicide and suicidal ideation for brand compared with generic central nervous system drugs. Drug Saf. 2018;41(4):363–76.

    Article  CAS  Google Scholar 

  2. Suggs CM, Levin RL, Mosholder AD, Swain RS, Zhao L. Comment on: “Mixed approach retrospective analyses of suicide and suicidal ideation for brand compared with generic central nervous system drugs”. Drug Saf. 2018. https://doi.org/10.1007/s40264-018-0726-3.

    Article  PubMed  Google Scholar 

  3. U.S. Food and Drug Administration. FDA Adverse Events Reporting System (FAERS) Public Dashboard 2018. https://www.fda.gov/aboutfda/workingatfda/fellowshipinternshipgraduatefacultyprograms/pharmacystudentexperientialprogramcder/ucm591384.htm. Accessed 3 Sept 2018.

  4. U.S. Food and Drug Administration. FDA perspective on MedDRA® MedDRA® coding quality in postmarketing Safety Report 2012. https://www.meddra.org/sites/default/files/page/documents_insert/Informal_EU_MedDRA_Usergroup_31Oct2012_x.pdf. Accessed 3 Sept 2018.

  5. Kimura G, Kadoyama K, Brown JB, Nakamura T, Miki I, Nisiguchi K, et al. Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Int J Med Sci. 2015;12(2):135–40.

    Article  CAS  Google Scholar 

  6. U.S. Food and Drug Administration. FDA List of Authorized Generic Drugs: U.S. Food Drug Administration. 2015. http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/abbreviatednewdrugapplicationandagenerics/ucm126389.htm. Accessed 3 Sept 2018.

Download references

Author information

Authors and Affiliations

  1. Department of Health Outcomes Research and Policy, Harrison School of Pharmacy, Auburn University, 2316 Walker Building, Auburn, AL, 36849, USA

    Richard A. Hansen, Ning Cheng, Md. Motiur Rahman, Yasser Alatawi & Jingjing Qian

  2. Biomedical Informatics Research Center, Marshfield Clinic Research Institute, Marshfield, WI, USA

    Peggy L. Peissig & Richard L. Berg

  3. Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA

    C. David Page

  4. Department of Computer Science, University of Wisconsin, Madison, WI, USA

    C. David Page

Authors
  1. Richard A. Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ning Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Md. Motiur Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasser Alatawi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jingjing Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peggy L. Peissig
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Richard L. Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. David Page
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard A. Hansen.

Ethics declarations

Funding

No sources of funding were used to prepare this letter. The US FDA supported the study described in the original paper [1]. Views expressed in written materials or publications and by speakers do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.

Conflict of interest

In the past 3 years, Richard Hansen has provided expert testimony for Daiichi Sankyo. Ning Cheng, Md. Motiur Rahman, Yasser Alatawi, Jingjing Qian, Peggy L. Peissig, Richard L. Berg, and David Page have no conflicts of interest that are directly relevant to the content of this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hansen, R.A., Cheng, N., Rahman, M.M. et al. Authors' Reply to Courtney Suggs and Colleagues’ Comment on: “Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs”. Drug Saf 41, 1423–1424 (2018). https://doi.org/10.1007/s40264-018-0728-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-018-0728-1

Keywords

Search

Navigation